Latest news
{{'2026-10-01T10:45:00Z' | dateFormatFilter}}
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
{{'2026-09-30T12:30:00Z' | dateFormatFilter}}
Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
{{'2026-09-30T09:45:00Z' | dateFormatFilter}}
People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
